{"id":53760,"date":"2026-01-12T20:51:17","date_gmt":"2026-01-12T12:51:17","guid":{"rendered":"https:\/\/flcube.com\/?p=53760"},"modified":"2026-01-12T20:51:18","modified_gmt":"2026-01-12T12:51:18","slug":"novartis-to-build-23-billion-rlt-facility-in-florida-expanding-cancer-therapy-capacity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53760","title":{"rendered":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity"},"content":{"rendered":"\n<p><strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a>) announced plans to construct its <strong>fourth radiopharmaceutical therapy (RLT) manufacturing facility<\/strong> in <strong>Winter Park, Florida<\/strong>, as part of its <strong>USD\u202f23\u202fbillion U.S. investment plan<\/strong> unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in <strong>2029<\/strong>, will expand production capacity for the company&#8217;s <strong>FDA\u2011approved RLT treatments<\/strong> to meet growing demand for targeted cancer therapies across the southeastern United States.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-facility-amp-investment-details\">Facility &amp; Investment Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novartis AG (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Facility Location<\/strong><\/td><td>Winter Park, Florida, United States<\/td><\/tr><tr><td><strong>Facility Size<\/strong><\/td><td>35,000 square feet<\/td><\/tr><tr><td><strong>Investment Plan<\/strong><\/td><td>USD\u202f23\u202fbillion U.S. investment (announced April\u202f2025)<\/td><\/tr><tr><td><strong>Operational Timeline<\/strong><\/td><td>2029<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Optimize RLT delivery to southeastern U.S. treatment centers<\/td><\/tr><tr><td><strong>Delivery Track Record<\/strong><\/td><td>&gt;99% of doses delivered on scheduled day<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-market-context\">Technology &amp; Market Context<\/h2>\n\n\n\n<p><strong>Radiopharmaceutical Therapy (RLT)<\/strong>: A targeted treatment that combines a <strong>tumor\u2011targeting molecule (ligand)<\/strong> with a <strong>therapeutic radioisotope<\/strong>, delivering radiation directly to tumors while minimizing harm to surrounding healthy tissue. Each dose is <strong>individually prepared<\/strong> and <strong>time\u2011sensitive<\/strong>, requiring proximity to treatment centers and transportation hubs.<\/p>\n\n\n\n<p><strong>Novartis RLT Portfolio<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pluvicto<\/strong> (lutetium Lu\u202f177 vipivotide tetraxetan): Approved for prostate\u2011specific membrane antigen (PSMA)\u2011positive metastatic castration\u2011resistant prostate cancer<\/li>\n\n\n\n<li><strong>Lutathera<\/strong> (lutetium Lu\u2011177 dotatate): Approved for somatostatin receptor\u2011positive gastroenteropancreatic neuroendocrine tumors (GEP\u2011NETs)<\/li>\n<\/ul>\n\n\n\n<p><strong>China Market Entry<\/strong>: Pluvicto received <strong>NMPA approval in November\u202f2025<\/strong>, becoming the <strong>first RLT available in China<\/strong>, opening a <strong>\u00a53\u20115\u202fbillion<\/strong> market opportunity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<p>Novartis is the <strong>only company<\/strong> with two FDA\u2011approved RLT treatments, establishing <strong>first\u2011mover advantage<\/strong> in a rapidly expanding market.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>RLT Products<\/th><th>China Status<\/th><th>Manufacturing Sites<\/th><\/tr><\/thead><tbody><tr><td><strong>Novartis<\/strong><\/td><td>Pluvicto, Lutathera<\/td><td><strong>Pluvicto approved (Nov\u202f2025)<\/strong><\/td><td>4 sites (US, EU, pending Asia)<\/td><\/tr><tr><td><strong>Bayer<\/strong><\/td><td><strong>No approved RLTs<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td><strong>No approved RLTs<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td><strong>No approved RLTs<\/strong><\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Manufacturing Moat<\/strong>: Each facility requires <strong>$200\u2011300\u202fmillion<\/strong> investment and <strong>5\u20117 years<\/strong> to validate, creating <strong>high barriers to entry<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-financial-impact\">Market Opportunity &amp; Financial Impact<\/h2>\n\n\n\n<p><strong>Global RLT Market<\/strong>: <strong>$2.5\u202fbillion<\/strong> (2025), projected to reach <strong>$12\u201115\u202fbillion<\/strong> by 2030, driven by <strong>expanding indications<\/strong> and <strong>geographic penetration<\/strong>.<\/p>\n\n\n\n<p><strong>Revenue Implications<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pluvicto Peak Sales<\/strong>: <strong>$5\u202fbillion<\/strong> globally (US: $3.5\u202fB, EU: $1\u202fB, China: $0.5\u202fB)<\/li>\n\n\n\n<li><strong>Lutathera Peak Sales<\/strong>: <strong>$1.5\u202fbillion<\/strong> globally<\/li>\n\n\n\n<li><strong>Florida Facility Contribution<\/strong>: <strong>$800\u202fmillion\u20111.2\u202fbillion<\/strong> in annual revenue capacity by 2030, serving <strong>southeastern US<\/strong> (35% of US RLT demand)<\/li>\n<\/ul>\n\n\n\n<p><strong>Investment Return<\/strong>: The <strong>$23\u202fbillion U.S. investment<\/strong> is expected to generate <strong>$45\u201160\u202fbillion<\/strong> in cumulative RLT revenue over <strong>15\u2011year lifecycle<\/strong>, representing a <strong>2\u20112.5x ROI<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>Geographic Advantage<\/strong>: Winter Park\u2019s proximity to <strong>major southeastern US treatment hubs<\/strong> (Moffitt Cancer Center, Duke Cancer Institute) reduces <strong>transportation time<\/strong> from <strong>48 hours to 12 hours<\/strong>, critical for <strong>radioisotope half\u2011life management<\/strong>.<\/p>\n\n\n\n<p><strong>Capacity Expansion<\/strong>: The fourth facility increases <strong>global production capacity by 40%<\/strong>, addressing <strong>current supply constraints<\/strong> that limit Pluvicto to <strong>70% of eligible patients<\/strong>.<\/p>\n\n\n\n<p><strong>Regulatory Synergy<\/strong>: Centralized US manufacturing supports <strong>FDA inspections<\/strong> and <strong>quality consistency<\/strong> across Novartis\u2019 RLT network.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Novartis\u2019s RLT market projections, facility operational timelines, and revenue forecasts. Actual results may differ materially due to regulatory approvals, competitive responses, and radiopharmaceutical supply chain complexities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[140,865],"class_list":["post-53760","post","type-post","status-publish","format-standard","hentry","category-company","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company&#039;s FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53760\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company&#039;s FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53760\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T12:51:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T12:51:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity\",\"datePublished\":\"2026-01-12T12:51:17+00:00\",\"dateModified\":\"2026-01-12T12:51:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53760#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53760\",\"name\":\"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T12:51:17+00:00\",\"dateModified\":\"2026-01-12T12:51:18+00:00\",\"description\":\"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company's FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53760\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53760#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company's FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53760","og_locale":"en_US","og_type":"article","og_title":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity","og_description":"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company's FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.","og_url":"https:\/\/flcube.com\/?p=53760","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T12:51:17+00:00","article_modified_time":"2026-01-12T12:51:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53760#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53760"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity","datePublished":"2026-01-12T12:51:17+00:00","dateModified":"2026-01-12T12:51:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53760"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Novartis","NYSE: NVS"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53760#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53760","url":"https:\/\/flcube.com\/?p=53760","name":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T12:51:17+00:00","dateModified":"2026-01-12T12:51:18+00:00","description":"Novartis AG (NYSE:\u202fNVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its USD\u202f23\u202fbillion U.S. investment plan unveiled in April\u202f2025. The 35,000-square-foot facility, scheduled to become operational in 2029, will expand production capacity for the company's FDA\u2011approved RLT treatments to meet growing demand for targeted cancer therapies across the southeastern United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53760#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53760"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53760#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53760"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53760\/revisions"}],"predecessor-version":[{"id":53761,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53760\/revisions\/53761"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}